IRICoR, Université de Montréal and Medigene sign collaboration and exclusive licensing option on novel cancer antigens

Montréal and Martinsried/Munich, 30 January 2020 IRICoR, a pan-Canadian drug discovery research commercialization centre and the Université de Montréal (UdeM) announce today that they have entered into a research collaboration on novel cancer antigens for highly specific immunotherapies with Medigene, a clinical-stage immuno-oncology company focusing on the development of T cell immunotherapies.

UdeM’s research team, led by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer (IRIC), will provide Medigene with tumor-specific antigens (TSAs) which they discovered using their proprietary platform, as novel targets for various cancer indications, particularly for solid tumors.

To read the press release, click here.

© 2008-2020 IRICoR